Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program

Hematological Oncology, EarlyView.

Source: Hematological Oncology - August 3, 2018 Category: Hematology Authors: LorenzoTonialini , MaurizioBonfichi , SimoneFerrero , GiacomoMalipiero , AndreaNozza , LisaArgnani , Pier LuigiZinzani Source Type: research